ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Abiomed, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
272
ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Abiomed, Inc. Investors of Important Deadline in Securities Class Action – ABMD

NEW YORK, Aug. 31, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”) of the important October 7, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Abiomed investors under the federal securities laws.

To join the Abiomed class action, go to http://www.rosenlegal.com/cases-register-1645.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) ABIOMED’s revenue growth was in decline; (2) ABIOMED did not have a sufficient plan in place to stem its declining revenue growth;  (3) ABIOMED was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, ABIOMED was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (5) as a result, ABIOMED’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 7, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1645.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com .

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.   Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:       Laurence Rosen, Esq.       Phillip Kim, Esq.       The Rosen Law Firm, P.A.       275 Madison Avenue, 34 th Floor       New York, NY 10016       Tel: (212) 686-1060       Toll Free: (866) 767-3653       Fax: (212) 202-3827       lrosen@rosenlegal.com       pkim@rosenlegal.com       cases@rosenlegal.com       www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 545

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 791

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 526

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 112

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 129

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 188

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 190

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 138

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 40

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 309

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Volvo Ends LiDAR Partnership: What This Means for LAZR Stock

Updated Category News Views 315

Volvo's Shift Away from LiDAR Technology Recently, the Swedish automaker Volvo announced its decision to cease its partnership with Luminar Technologies Inc. (NASDAQ: LAZR). This bold move has caught the attention of the automotive industry, especially those tracking advancements in autonomous vehicle technology. By not integrating LiDAR technology into its forthcoming...

Continue Reading
Samsung and Xiaomi Face Antitrust Findings in India Market

Updated Category News Views 157

Samsung and Xiaomi Face Antitrust Investigation in India Samsung, Xiaomi, and various other smartphone manufacturers are under serious scrutiny for allegedly colluding with major e-commerce platforms in India, undermining fair market practices. The Competition Commission of India (CCI) has gathered evidence that suggests these companies coordinated with Amazon and...

Continue Reading
Bonnie Navin Honored as Top 25 Medical Malpractice Attorney

Updated Category News Views 164

Bonnie Navin Attributes and Accolades Bonnie Navin of Rubenstein Law has recently earned a significant honor by being selected as a member of the Medical Malpractice Trial Lawyers Association - Top 25. This elite recognition is awarded to the most distinguished attorneys specializing in medical malpractice across the nation, and it showcases Navin's exceptional skill and...

Continue Reading
Top Dividend Stocks for Long-Term Passive Income Investors

Updated Category News Views 99

Success in the business world has never been a cakewalk. Many new ventures stumble within a decade, and only a handful manage to stay afloat while also boasting a robust and growing dividend program. Companies that consistently dish out dividends reflect financial health, but there’s more to the story. Take Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE:...

Continue Reading
Cathie Wood Predicts Deflationary Boom Amid Market Decline

Updated Category News Views 404

Cathie Wood's Deflationary Boom Forecast Amid Market Turbulence CEO of Ark Funds, Cathie Wood, has made bold predictions regarding a potential "deflationary boom" despite significant losses in the stock market. Recent trading sessions saw renowned tech stocks, collectively known as the Magnificent Seven, lose about $780 billion in market capitalization in a single day,...

Continue Reading